Specialty Drug ‘Doom Loop:’ Manufacturers Fight Against Becoming Primary Payers For Own Drugs

Drug Channels’ Adam Fein described the ongoing and escalating battle between manufacturers and payers over the cost of specialty drugs during a recent webinar.

The Conflict Between Payers and Manufacturers Can Be Tough On Patients. • Source: Shutterstock

The latest iteration of the commercial insurance tactics aimed at mitigating the cost of expensive specialty drugs involves tapping patient assistance programs to the extent that manufacturers can bear the entire cost of their drugs.

Known as “alternative funding,” such programs represent the most controversial of the moves and counter-moves employed by payers in recent...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet